Login / Signup

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Phillip J MeaseAtul A DeodharDésirée Mfm van der HeijdeFrank BehrensAlan J KivitzJeffrey NealJonghyeon KimShalabh SinghalMiroslawa NowakSubhashis Banerjee
Published in: Annals of the rheumatic diseases (2022)
NCT03881059.
Keyphrases
  • open label
  • randomized controlled trial
  • placebo controlled
  • double blind